An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
StatPearls [Internet].
Treasure Island (FL): StatPearls Publishing; 2026 Jan-.
Top results in this bookTable of Contents
Pharmacotherapy for Adults With Alcohol-Use Disorders in Outpatient Settings [Internet].
Jonas DE, Amick HR, Feltner C, et al.
Rockville (MD): Agency for Healthcare Research and Quality (US); 2014 May. (Comparative Effectiveness Reviews, No. 134.)
Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence.
Geneva: World Health Organization; 2009.
Community Management of Opioid Overdose.
Geneva: World Health Organization; 2014.
Clinical Review Report: Naltrexone Hydrochloride and Bupropion Hydrochloride (Contrave): (Bausch Health, Canada Inc.): Indication: An adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., controlled hypertension, type 2 diabetes mellitus, or dyslipidemia) [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Jul.
Management of Suspected Opioid Overdose With Naloxone by Emergency Medical Services Personnel [Internet].
Chou R, Korthuis PT, McCarty D, et al.
Rockville (MD): Agency for Healthcare Research and Quality (US); 2017 Nov. (Comparative Effectiveness Reviews, No. 193.)
Buprenorphine/Naloxone Versus Methadone for the Treatment of Opioid Dependence: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness and Guidelines [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Sep 2.
Clinical Review Report: Tapentadol Hydrochloride Extended-Release Tablet (Nucynta Extended-Release): (Paladin Labs Inc.): Indication: Management of pain severe enough to require daily, continuous, long-term opioid treatment, and: that is opioid responsive; and for which alternative treatment options are inadequate. Tapentadol extended-release tablet is not indicated as an as-needed (prn) analgesic [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Oct.
Medications for Opioid Use Disorder: For Healthcare and Addiction Professionals, Policymakers, Patients, and Families: Updated 2021 [Internet].
Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2018. (Treatment Improvement Protocol (TIP) Series, No. 63.)
Opioid Treatments for Chronic Pain [Internet].
Chou R, Hartung D, Turner J, et al.
Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Apr. (Comparative Effectiveness Review, No. 229.)
Pharmacoeconomic Review Report: Naltrexone Hydrochloride and Bupropion Hydrochloride (Contrave): (Bausch Health, Canada Inc.): Indication: An adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., controlled hypertension, type 2 diabetes mellitus, or dyslipidemia) [Internet].
Intranasal and Intramuscular Naloxone for Opioid Overdose in the Pre-Hospital Setting: A Review of Comparative Clinical and Cost-Effectiveness, and Guidelines [Internet].
Peprah K, Frey N.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Mar 16.
Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use.
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse; Phillips JK, Ford MA, Bonnie RJ, editors.
Washington (DC): National Academies Press (US); 2017 Jul 13.
Crushed Buprenorphine or Buprenorphine-Naloxone for Opioid Dependency: A Review of the Clinical Effectiveness and Guidelines [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Jul 18.
Take-home naloxone in multicentre emergency settings: the TIME feasibility cluster RCT.
Snooks H, Benger J, Bell F, et al.
Southampton (UK): National Institute for Health and Care Research; 2024 Oct. (Health Technology Assessment, No. 28.74.)
Clinical Review Report: Buprenorphine extended-release injection (Sublocade): (Indivior Canada, Ltd.): Indication: For the management of moderate-to-severe opioid use disorder in adult patients who have been inducted and clinically stabilized on a transmucosal buprenorphine-containing product [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jul.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].
York (UK): Centre for Reviews and Dissemination (UK); 1995-.
Suboxone versus Methadone for the Treatment of Opioid Dependence: A Review of the Clinical and Cost-effectiveness [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2013 Nov 14.
Spinal Injury: Assessment and Initial Management.
National Clinical Guideline Centre (UK).
London: National Institute for Health and Care Excellence (NICE); 2016 Feb. (NICE Guideline, No. 41.)
Review of Four CARA Programs and Preparing for Future Evaluations.
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Review of Specific Programs in the Comprehensive Addiction and Recovery Act; Stratton K, McHugh MK, Amaro H, et al., editors.
Washington (DC): National Academies Press (US); 2023 Mar 23.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on